Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 27, 2024

Outcomes of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as Initial Therapy in Patients With HR+/HER2− Advanced Breast Cancer

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3
Ann. Oncol 2024 May 08;[EPub Ahead of Print], MP Goetz, M Toi, J Huober, J Sohn, O Trédan, IH Park, M Campone, SC Chen, LM Manso, S Paluch-Shimon, OC Freedman, J O'Shaughnessy, X Pivot, SM Tolaney, S Hurvitz, A Llombart-Cussac, V André, A Saha, G van Hal, A Shahir, H Iwata, SRD Johnston

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading